About

Global Patient Dialogues: What are the benefits of our new patient engagement approach?

• Patient Organizations and representative patient populations drive the dialogue as experts.
• Patients are inclusive of family, care partners, and other members of the patient community.
• Participants just register for the meeting with an appropriate registration fee; no grants or contracts are involved.
• All types of health care innovators in the private and public sector will engage with patients making the dialogue applicable to many aspects of research and healthcare innovation.
• Our use of the latest quality patient engagement regulatory guidance and frameworks are key to having a trusted approach and generating valid conclusions.
• Our unique capability to learn from patients across the globe is expected to provide sustainable interest and value to all stakeholders.

Current approaches to holding externally-led, voice-of-the-patient meetings are costly, inefficient, and slow. They place a high burden on patients and patient groups who are typically resource-constrained. They are time-consuming and burdensome because they require fundraising by patient groups to identify industry sponsors and contracts established among multiple patient groups and multiple funders.

These relationships may raise concerns about the independence of patient groups from influence by the companies involved. Because of these barriers, several industry leaders /stakeholders (including health system leaders) are engaging unaffiliated patients, therefore Patient Organization expertise is not optimized. The Global Patient Dialogue Series eliminates these hurdles for patient groups and stakeholders while delivering a sustainable solution to address the interest from regulators for patient organizations to identify and organize patient-focused collaborations to accelerate public input in multiple disease areas, using the process established through the FDA-PFDD as a model.